SCAND2P: A Drug Target / Disease Biomarker (G54581)

Target Name: SCAND2P

NCBI ID: G54581

SCAND2P

Other Name(s): SCAND2P variant 1 | SCAND2 | SCAN domain containing 2 pseudogene, transcript variant 1 | SCAN domain containing 2 pseudogene

SCAND2P: A Drug Target / Disease Biomarker

SCAND2P, also known as NEDD8-activating enzyme 2, is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the detoxification process, which is responsible for breaking down harmful substances that are found in the body. SCAND2P is highly expressed in the liver, and it has been shown to play a crucial role in the regulation of drug resistance.

Recent studies have suggested that SCAND2P may also be a drug target or biomarker. For example, studies have shown that inhibiting the activity of SCAND2P has been shown to increase the sensitivity of cancer cells to chemotherapy drugs. Additionally, altered expression of SCAND2P has been observed in various diseases, including cancer, which may indicate its role in the development and progression of these diseases.

One of the key reasons for the potential drug targeting of SCAND2P is its involvement in drug resistance. Drug resistance is a phenomenon that occurs when cancer cells become less responsive to drugs, making them more difficult to treat. SCAND2P is a key enzyme in the detoxification process, which means that it is involved in the breakdown of many drugs. By inhibiting the activity of SCAND2P, it may be possible to increase the effectiveness of drugs and improve the treatment outcomes for cancer patients.

Another potential mechanism by which SCAND2P may be targeted as a drug may be its role in the regulation of cellular signaling pathways. SCAND2P has been shown to be involved in the regulation of several signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cellular processes such as cell growth, differentiation, and survival. By targeting SCAND2P, researchers may be able to disrupt these signaling pathways and induce cellular changes that could be useful for the development of new cancer treatments.

In addition to its potential drug targeting properties, SCAND2P has also been shown to be a potential biomarker for several diseases. For example, altered expression of SCAND2P has been observed in several types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have suggested that SCAND2P may be involved in the regulation of cellular processes that are critical for cancer cell growth and survival, such as the angiogenesis (the formation of new blood vessels) and the immune response.

Overall, SCAND2P is a protein that has significant potential as a drug target or biomarker. Its involvement in the detoxification process, as well as its potential role in the regulation of cellular signaling pathways, make it an attractive target for researchers to investigate further. As more research is conducted on SCAND2P, it is likely that new insights into its biology and potential uses will emerge.

Protein Name: SCAN Domain Containing 2 Pseudogene

The "SCAND2P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCAND2P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets